225 related articles for article (PubMed ID: 38042824)
1. The role of Traditional Chinese medicine in anti-HBV: background, progress, and challenges.
Ge F; Yang Y; Bai Z; Si L; Wang X; Yu J; Xiao X; Liu Y; Ren Z
Chin Med; 2023 Dec; 18(1):159. PubMed ID: 38042824
[TBL] [Abstract][Full Text] [Related]
2. Nucleos(t)ide analogues altered quasispecies composition of hepatitis B virus (HBV)-resistant mutations in serum HBV DNA and serum HBV RNA.
Liao H; Zhang H; Shao J; Li X; Zheng WV; Li L; Yu G; Si L; Zhou T; Yao Z; Dai J; Xu D; Cheng G; Qu J; Liu Y; Chen J; Lu F
J Med Virol; 2023 Mar; 95(3):e28612. PubMed ID: 36840474
[TBL] [Abstract][Full Text] [Related]
3. Update on hepatitis B virus infection.
You CR; Lee SW; Jang JW; Yoon SK
World J Gastroenterol; 2014 Oct; 20(37):13293-305. PubMed ID: 25309066
[TBL] [Abstract][Full Text] [Related]
4. Safety and therapeutic effects of anti-fibrotic Traditional Chinese Medicine Fuzheng Huayu on persistent advanced stage fibrosis following 2 years entecavir treatment: Study protocol for a single arm clinical objective performance criteria trial.
Chen Y; Zhao Z; Fan H; Li Z; He Y; Liu C
Contemp Clin Trials Commun; 2020 Sep; 19():100601. PubMed ID: 32642592
[TBL] [Abstract][Full Text] [Related]
5. Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome.
Wu D; Ning Q
J Infect Dis; 2017 Nov; 216(suppl_8):S771-S777. PubMed ID: 29156046
[TBL] [Abstract][Full Text] [Related]
6. Aiming for cure in HBV and HDV infection.
Petersen J; Thompson AJ; Levrero M
J Hepatol; 2016 Oct; 65(4):835-848. PubMed ID: 27270043
[TBL] [Abstract][Full Text] [Related]
7. Latest developments in the treatment of hepatitis B.
Dandri M; Petersen J
Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
[TBL] [Abstract][Full Text] [Related]
8. [Oral nucleos(t)ide analogues antiviral therapy reduces HBV-related HCC: consensus and contention].
Han C; Dou XG
Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):293-296. PubMed ID: 33979951
[TBL] [Abstract][Full Text] [Related]
9. [Demographic characteristics and associated influencing factors in treated patients with chronic hepatitis B with hypoviremia : a single-center retrospective cross-sectional study].
Li T; Kong Y; Liu YY; Liu TF; Ma AD; Li LQ; Pei ZY; Zhang LY
Zhonghua Gan Zang Bing Za Zhi; 2023 Jan; 31(1):42-48. PubMed ID: 36948848
[No Abstract] [Full Text] [Related]
10. Toward Curative Immunomodulation Strategies for Chronic Hepatitis B Virus Infection.
Zhu W; Liu H; Zhang X
ACS Infect Dis; 2019 May; 5(5):703-712. PubMed ID: 30907080
[TBL] [Abstract][Full Text] [Related]
11. HBV replication inhibitors.
Pierra Rouviere C; Dousson CB; Tavis JE
Antiviral Res; 2020 Jul; 179():104815. PubMed ID: 32380149
[TBL] [Abstract][Full Text] [Related]
12. Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis.
Liu J; Wang T; Zhang W; Cheng Y; He Q; Wang FS
Hepatol Int; 2020 Dec; 14(6):958-972. PubMed ID: 33185803
[TBL] [Abstract][Full Text] [Related]
13. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.
Zhang MY; Zhu GQ; Shi KQ; Zheng JN; Cheng Z; Zou ZL; Huang HH; Chen FY; Zheng MH
Oncotarget; 2016 May; 7(21):30642-58. PubMed ID: 27121321
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular Carcinoma and Hepatitis: Advanced Diagnosis and Management with a Focus on the Prevention of Hepatitis B-Related Hepatocellular Carcinoma.
Kim SR; Kim SK
Diagnostics (Basel); 2023 Oct; 13(20):. PubMed ID: 37892033
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
Jansen L; Kootstra NA; van Dort KA; Takkenberg RB; Reesink HW; Zaaijer HL
J Infect Dis; 2016 Jan; 213(2):224-32. PubMed ID: 26216905
[TBL] [Abstract][Full Text] [Related]
16. Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues.
Rapti I; Hadziyannis S
World J Hepatol; 2015 May; 7(8):1064-73. PubMed ID: 26052395
[TBL] [Abstract][Full Text] [Related]
17. [The potential use of serum HBV RNA to guide the functional cure of chronic hepatitis B].
Lu FM; Wang J; Chen XM; Jiang JN; Zhang WH; Zhao JM; Ren H; Hou JL; Xia NS
Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):105-110. PubMed ID: 28297795
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
Yuen MF; Asselah T; Jacobson IM; Brunetto MR; Janssen HLA; Takehara T; Hou JL; Kakuda TN; Lambrecht T; Beumont M; Kalmeijer R; Guinard-Azadian C; Mayer C; Jezorwski J; Verbinnen T; Lenz O; Shukla U; Biermer M;
Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):790-802. PubMed ID: 37442152
[TBL] [Abstract][Full Text] [Related]
19. Current and novel modalities for management of chronic hepatitis B infection.
Salama II; Sami SM; Salama SI; Abdel-Latif GA; Shaaban FA; Fouad WA; Abdelmohsen AM; Raslan HM
World J Hepatol; 2023 May; 15(5):585-608. PubMed ID: 37305370
[TBL] [Abstract][Full Text] [Related]
20. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B.
Mirandola S; Campagnolo D; Bortoletto G; Franceschini L; Marcolongo M; Alberti A
J Viral Hepat; 2011 Jul; 18(7):e212-6. PubMed ID: 21692935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
